Issei Saeki

1.1k total citations
53 papers, 583 citations indexed

About

Issei Saeki is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Issei Saeki has authored 53 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hepatology, 31 papers in Epidemiology and 14 papers in Surgery. Recurrent topics in Issei Saeki's work include Liver Disease Diagnosis and Treatment (29 papers), Hepatocellular Carcinoma Treatment and Prognosis (27 papers) and Liver Disease and Transplantation (17 papers). Issei Saeki is often cited by papers focused on Liver Disease Diagnosis and Treatment (29 papers), Hepatocellular Carcinoma Treatment and Prognosis (27 papers) and Liver Disease and Transplantation (17 papers). Issei Saeki collaborates with scholars based in Japan and United States. Issei Saeki's co-authors include Isao Sakaida, Takahiro Yamasaki, Taro Takami, Tsuyoshi Ishikawa, Toshihiko Matsumoto, Shuji Terai, Masaki Maeda, Takuya Iwamoto, Isao Hidaka and Koichi Uchida and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Issei Saeki

52 papers receiving 573 citations

Peers

Countries citing papers authored by Issei Saeki

Since Specialization

Citations

This map shows the geographic impact of Issei Saeki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Issei Saeki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Issei Saeki more than expected).

Fields of papers citing papers by Issei Saeki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Issei Saeki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Issei Saeki. The network helps show where Issei Saeki may publish in the future.

Co-authorship network of co-authors of Issei Saeki

This figure shows the co-authorship network connecting the top 25 collaborators of Issei Saeki. A scholar is included among the top collaborators of Issei Saeki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Issei Saeki. Issei Saeki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma 2025 ·Anticancer Research ·(unknown), Issei Saeki, (unknown), Tomokazu Kawaoka, (unknown), Joji Tani, Takeshi Terashima, (unknown), Shiro Oka, Tetsuji Takayama, Hideki Kobara, Taro Yamashita, Norio Akuta, Takahiro Yamasaki, (unknown)	1
2	Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma 2024 ·Liver Cancer ·(unknown), Yutaka Suehiro, Issei Saeki, (unknown), (unknown), Toshihiko Matsumoto, Shingo Higaki, (unknown), Chieko Suzuki, Naoko Okayama, M. Nishioka, Kiyoshi Ichihara, Hiroaki Nagano, Isao Sakaida, Taro Takami, Takahiro Yamasaki	2
3	Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy 2023 ·Cancer Medicine ·Issei Saeki, Takahiro Yamasaki, (unknown), Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Reo Kawano, Kazuaki Chayama, Naoya Kato, Taro Takami	2
4	Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma 2023 ·Hepatology International ·Issei Saeki, Yutaka Suehiro, (unknown), (unknown), (unknown), Takashi Oono, (unknown), (unknown), Toshihiko Matsumoto, Tsuyoshi Ishikawa, Mototsugu Shimokawa, Akihiro Tamori, Norifumi Kawada, Yasuyuki Tamai, Motoh Iwasa, Hayato Nakagawa, Hiroaki Nagano, Taro Takami, Takahiro Yamasaki	10
5	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment 2022 ·Liver Cancer ·Takahiro Yamasaki, Issei Saeki, (unknown), Toshihiko Matsumoto, Yutaka Suehiro, Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Taro Takami, Kazuaki Chayama, Naoya Kato, Isao Sakaida	7
6	A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension 2022 ·Journal of Gastroenterology ·Tsuyoshi Ishikawa, (unknown), Tsuyoshi Fujioka, (unknown), (unknown), Ryo Sasaki, (unknown), (unknown), Takashi Oono, Issei Saeki, Taro Takami	1
7	Albumin–bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma 2020 ·Clinical Nutrition ·(unknown), Issei Saeki, Takahiro Yamasaki, Ryo Sasaki, (unknown), Takashi Oono, Masaki Maeda, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida	10
8	Usefulness of adult medaka fish as a model for the evaluation of alcoholic fatty liver 2019 ·Alcohol ·Koichi Fujisawa, Taro Takami, (unknown), (unknown), Hisashi Hoshida, Issei Saeki, Toshihiko Matsumoto, Isao Hidaka, Naoki Yamamoto, Isao Sakaida	7
9	A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification 2019 ·PLoS ONE ·Tsuyoshi Ishikawa, Ryo Sasaki, (unknown), (unknown), Issei Saeki, Takuya Iwamoto, Isao Hidaka, Taro Takami, Isao Sakaida	11
10	Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy 2019 ·PLoS ONE ·Issei Saeki, Takahiro Yamasaki, Masaki Maeda, (unknown), Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida	14
11	Evaluation of the Effects of Cultured Bone Marrow Mesenchymal Stem Cell Infusion on Hepatocarcinogenesis in Hepatocarcinogenic Mice With Liver Cirrhosis 2019 ·Transplantation Proceedings ·Keita Matsuura, Taro Takami, Masaki Maeda, (unknown), Koichi Fujisawa, Issei Saeki, Toshihiko Matsumoto, Isao Hidaka, Naoki Yamamoto, Isao Sakaida	1
12	No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma 2018 ·Liver Cancer ·Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Reo Kawano, (unknown), Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida	28
13	Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion 2018 ·Journal of Gastroenterology and Hepatology ·Tsuyoshi Ishikawa, Ryo Sasaki, (unknown), Takashi Matsuda, Masaki Maeda, Takuya Iwamoto, Issei Saeki, Isao Hidaka, Taro Takami, Isao Sakaida	12
14	Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy 2018 ·World Journal of Hepatology ·Issei Saeki, Takahiro Yamasaki, Masaki Maeda, (unknown), Takuya Iwamoto, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Yoshio Marumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Yutaka Suehiro, Taro Takami, Isao Sakaida	19
15	Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function 2016 ·World Journal of Gastroenterology ·Taro Takami, Takahiro Yamasaki, Issei Saeki, Toshihiko Matsumoto, Yutaka Suehiro, Isao Sakaida	13
16	Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma 2012 ·Journal of Gastroenterology ·Takahiro Yamasaki, Issei Saeki, (unknown), (unknown), Masaki Maeda, (unknown), Takuya Iwamoto, Isao Hidaka, Yohei Urata, Tsuyoshi Ishikawa, Taro Takami, (unknown), Koichi Uchida, Shuji Terai, Isao Sakaida	10
17	Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis 2012 ·Journal of Gastroenterology ·Issei Saeki, Shuji Terai, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Toshihiko Matsumoto, (unknown), (unknown), Takahiro Yamasaki, Isao Sakaida	35
18	Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: analysis of 114 cases 2011 ·Kanzo ·(unknown), Takahiro Yamasaki, (unknown), Issei Saeki, (unknown), (unknown), (unknown), Taro Takami, Seiji Kaino, (unknown), Shuji Terai, Isao Sakaida	6
19	Effect of a late evening snack using branched‐chain amino acid‐enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma 2010 ·Hepatology Research ·(unknown), Takahiro Yamasaki, (unknown), Issei Saeki, Kohsuke Okita, Shuji Terai, Isao Sakaida	34
20	Pilot Study of Combination Therapy With Transcatheter Arterial Infusion Chemotherapy Using Iodized Oil and Percutaneous Radiofrequency Ablation During Occlusion of Hepatic Blood Flow for Hepatocellular Carcinoma 2008 ·American Journal of Clinical Oncology ·(unknown), Takahiro Yamasaki, Issei Saeki, Kohsuke Okita, (unknown), Koichi Uchida, Shuji Terai, Isao Sakaida	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact